Causes of Mesenteric Vein Thrombosis
Mesenteric vein thrombosis results from a combination of Virchow's triad—stagnant blood flow, hypercoagulability, and endothelial damage—with identifiable causes found in approximately 64% of young patients, while 36% remain idiopathic. 1
Primary Etiologic Categories
Hypercoagulable States (Inherited)
The inherited thrombophilias represent critical causes that must be systematically evaluated:
- Factor V Leiden mutation 1
- Prothrombin gene mutation 1
- Protein S deficiency 1, 2
- Protein C deficiency 1
- Antithrombin deficiency 1
- Antiphospholipid syndrome 1
- Fibrinolysis shutdown (resistance to tissue plasminogen activator) 1
Acquired Hypercoagulable States
Malignancy is both a common risk factor and frequent cause of death in patients with mesenteric vein thrombosis, particularly abdominal malignancies. 3 Additional acquired causes include:
- Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, primary myelofibrosis) 3
- JAK2V617F mutation (detected in 20-40% of patients with splanchnic vein thrombosis even without overt myeloproliferative disorders) 3, 4, 5
- JAK2 exon 12 mutations (in patients without JAK2V617F) 3
- Paroxysmal nocturnal hemoglobinuria (PNH) 3
- Hematologic disorders 1
- Oral contraceptives and exogenous estrogen (hormone replacement therapy) 3, 1
Local Inflammatory/Surgical Causes
Inflammatory processes around the superior mesenteric vein directly trigger thrombosis through endothelial damage:
- Acute pancreatitis 1
- Inflammatory bowel disease 1
- Diverticulitis 6
- Recent abdominal surgery (splenectomy, bariatric surgery) 3, 1
- Abdominal mass 3
Systemic Conditions
Clinical Context and Risk Stratification
In young patients (<50 years), 36% of cases occur without obvious cause, necessitating comprehensive thrombophilia workup including JAK2V617F mutation testing even in the absence of overt myeloproliferative disease. 1
The presence of concurrent cancer significantly predicts decreased survival, with mesenteric vein thrombosis carrying a 30-day mortality rate of 20% and intestinal infarction occurring in 30-45% at diagnosis (19% fatal). 3
Key Diagnostic Pitfalls
Do not overlook JAK2V617F mutation testing—this mutation is now part of diagnostic assessment and is detected in 20-40% of splanchnic vein thrombosis patients without overt myeloproliferative disorders. 3, 4, 5
Consider PNH in patients with chronic hemolysis, as this rare clonal hematopoietic disorder has high propensity for splanchnic venous thrombosis. 3
Recent surgical trauma, particularly splenectomy or bariatric surgery, should immediately raise suspicion for superior mesenteric vein thrombosis in postoperative patients with abdominal pain. 3, 1